Membrane-less organelle pathology in ALS: identification of causes and rescuing factors (MLOMALS)

tArGeting brAIn cholesterol traNSporT in Alzheimer’s Disease (AGAINST-AD)

Low density lipoprotein receptor (LDLR)-independent effects of proprotein convertase subtilisin/kexin type 9 (PCSK9): role in modulating insulin-resistance, ectopic fat accumulation and low-grade inflammation

Pathogenesis of Chemotherapy-Induced Peripheral Neurotoxicity (Pa-CIPN)

Role of alpha-synuclein and LRRK2 in Levodopa-induced dyskinesia

Selective translation of androgen receptor isoform A to prevent polyQ mediated toxicity in Kennedy’s disease

Deciphering the role of ADAM10 and CAP2 in Age‐related Accumulation of deficits

Metabolic rewiring of diabetic heart: unveiling the role of lipoproteins on cardiac function

Drug repurposing as a novel strategy to discover pro-regenerative therapies for neurological diseases: the challenge of progressive multiple sclerosis

PIANO DI SOSTEGNO ALLA RICERCA 2015-2017 - TRANSITION GRANT LINEA 1B PROGETTO "UNIMI PER ERC STARTING E CONSOLIDATOR"

Molecular mechanisms regulating oligodendroglia functions and re-/myelination - Organizzazione convegno

Human and animal studies: a novel strategy against Alzheimer synaptic dysfunction

Inflammation in the pathophysiology of ageingrelated frailty: unravelling the contribution of blood platelets

The MDS on LDC: Tissue Sharing Programme

Study of the crosstalk between multiple pathways in the regulation of inflammatory processes in models of chronic and degenerative diseases

Molecular pathways in Schwannomatosis: exploiting in vitro models for the identification of new therapeutic targets

ENDOCRINE DISRUPTORS: INVESTIGATION OF THE EFFECTS ON THE IMMUNE AND NERVOUS SYSTEMS (EDoNIS)

Dysbindin-antipsychotics psychophamarcogenetics: a mouse-human translational study towards personalized healthcare in bipolar disorders

Combined Next-generation sequencing and in vivo approach to uncover the complex genetic basis of GnRH neuron deficiency

Piano di Sostegno alla Ricerca 2015-2017 - Linea 2 "Dotazione annuale per attività istituzionali" (anno 2018)

Treating pain to modulate frailty: a bench to bedside mechanism based model

Modulation of bone marrow macrophage plasticity by gametocytes, the transmission stages of malaria parasite

Unveiling the impact of ASGR1 deficiency on the immunoinflammatory signature during atherogenesis (ASGR1 )

Bioinformatics and cell reprogramming to develop an in vitro platform to discover new drugs for progressive multiple sclerosis (BRAVEinMS)

Bioinformatics and cell reprogramming to develop an in vitro platform to discover new drugs for progressive multiple sclerosis (BRAVEinMS)

Unveiling the role of the Irisin-BNDF axis in controlling muscle to brain metabolic crosstalk in anorexia nervosa

Extracellular vescicles in the pathogenesis of frontotemporal dementia

MicroRNAs in Frailty-Associated Cognitive Impairment (MATCh-In)

Medicina personalizzata per strategie innovative in malattie neuro-psichiatriche e vascolari (PerMedNet)

PCSK9 and cardiac function: bridging cellular lipid metabolism to mitochondrial function and heart failure (PCSK9)

Dipartimenti di Eccellenza 2018-2022 - Dipartimento di SCIENZE FARMACOLOGICHE E BIOMOLECOLARI

Strategie rimielinizzanti innovative per la sclerosi multipla: focus su GPR17, nuovo recettore coinvolto nel differenziamento oligodendrocitario

New generation drugs against Plasmodium falciparum trasmission for malaria eradication (I ANNO)

Fondo per il finanziamento delle attività base di ricerca - DIPARTIMENTO DI SCIENZE FARMACOLOGICHE E BIOMOLECOLARI

Studio e messa a punto di nuovi prodotti pro-e prebiotici per la prevenzione ed il trattamento di patologie infiammatorie quali la sindrome del colon irritabile e la dermatite atopica (SCIDA)

Linking PCSK9 to beta-cell physiology and glucose metabolism

Investigation on the possible role of micrornas in the regulation of chemical allergen potency

Wound Healing and Sutures in Unloading Conditions

Colchicine for Amyotrophic Lateral Sclerosis: a phase II, randomized, double blind, placebo controlled, multicenter clinical trial (Co-ALS)

Piano di Sostegno alla Ricerca 2015-2017 - Linea 2 "Dotazione annuale per attività istituzionali" (anno 2017)